The RESI (Redefining Early Stage Investments) kicks off
today in Boston, Massachusetts, where 200 early stage investors, 300
fundraising executives and 100 service providers will meet for a one-day
international partnering meeting that gives early stage life science companies
the chance to book target meetings with relevant investors.
RESI Conference activities include the RESI Innovation
Challenge, where attendees will use RESI cash tokens to “invest” in the
conference’s most compelling RESI Innovators. The invested capital will be
tallied and the Top 3 winners will receive an award at a cocktail reception at
the end of the day.
Investor panels will cover a wide range of topics, including
biotech angels to preclinical and phase I investors, phase II and III
investors, big pharma, corporate venture capital, NIH funding and resources for
startups, medical device investors, and more.
The vast lineup of early stage entrepreneur workshops
include topics ranging from fundraising boot camp and government grants and
contracts, to branding and messaging and how to research global investors.
The RESI Conference is an ongoing conference series that
will be establishing a global circuit for early stage life sciences companies
to source investors, create relationships, and eventually, get funding.
Following highly successful events in San Francisco and Houston, earlier this
year, the 2015 RESI conference in Boston is expected to be the biggest yet.
Upcoming RESI Conference schedules include San Francisco in
January 2016, Houston in April, Toronto in June, and Boston again next
September.
For more information, visit www.resiconference.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
